
wersenderf

RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: Art Unit / Team No.: Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

ARTI SHAH 703-308-4212

Raw Sequence Listing Error Summary

	ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 09/096, 749
1 ATTN	NEW RULES CASES: F Wrapped Nucleics	PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, V The number/text at the end of each line "wrapped" down This may occur if your file was retrieved in a word proce	to the next line. ssor after creating it.
2	Wrapped Aminos	Please adjust your right margin to .3, as this will preven The amino acid number/text at the end of each line "wra This may occur if your file was retrieved in a word proce Please adjust your right margin to .3, as this will preven	pped " down to the next line. essor after creating it.
3	Incorrect Line Length	The rules require that a line not exceed 72 characters in All text must be visible on page.	length. This includes spaces.
4	MIsaligned Amino Acid Numbering	The numbering under each 5th amino acid is misaligned between the numbering. It is recommended to delete any	
5	Non-ASCII	This file was not saved in ASCII (DOS) text, as required Please ensure your subsequent submission is saved in A	
6	Variable Length	Sequence(s) contain n's or Xaa's which represente As per the rules, each n or Xaa can only represent a sing Please present the maximum number of each residue ha indicate in the (ix) features section that some may be m	gle residue. ving vanable length and
, <u>V</u>	Wrong Designation	Sequence(s) Contain amino acid or nucleic acid de representations as per the Sequence Rules (Please refe	
8	Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please use the (2) INFORMATION FOR SEQ ID NO:X: (I) SEQUENCE CHARACTERISTICS:(Do not insert any (xI) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped	
		Please also adjust the "(iii) NUMBER OF SEQUENCES:	response to include the skipped sequence(s).
9	Skipped Sequences (NEW RULES)	Sequence(s) missing. If Intentional, please use the <210> sequence id number <400> sequence id number 000	following format for each skipped sequence.
	Use of N's or Xaa's (NEW RULES)	Use of N's and/or Xaa's have been detected in the Seque Use of <220> to <223> is MANDATORY if n's or Xaa's at	
	Use of <213>Organism (NEW RULES)	Sequence(s) are missing this mandatory field or	its response.
	Use of <220>Feature (NEW RULES)	Sequence(s) are missing the <220>Feature and ass Use of <220> to <223> is MANDATORY if <213>ORGAN (See "Federal Register," 6/01/98, Vol. 63, No. (Sec. 1.823 of new Sequence Rules)	IISM Is "Artificial" or "Unknown"
13	Wrong Format .	File submitted was In the alphabetical heading format of taggraphic and the submitted was In the alphabetical heading format of the "Requirements for Patent Applications Containing Nucleo Federal Register Notice, Vol. 63, No. 104, June 1, 1998, applies to applications filed on or after July 1, 1998. AKS-Biotechnology Systems Branch- 7/10	tide Sequence and/or Amino Acid Disclosures" p. 29620



RAW SEQUENCE LISTING PATENT APPLICATION US/09/096,749

DATE: 09/09/98 TIME: 15:58:54

INPUT SET: S28504.raw

This Raw Listing contains the General Information Section and those Sequences containing ERRORS.

Does Not Comply
Corrected Diskette Needed

```
SEQUENCE LISTING
 1
 2
 3
     (1)
            General Information
 4
 5
             (i) APPLICANT: Koieda, Shohei
 6
            (ii) TITLE OF THE INVENTION: ARTIFICIAL ANTIBODY POLYPEPTIDES
 7
 8
 9
            (iii) NUMBER OF SEQUENCES: 118
10
            (iv) CORRESPONDENCE ADDRESS:
11
              (A) ADDRESSEE: Schwegman, Lundberg, Woessner & Kluth P.A.
12
              (B) STREET: 121 South Eighth Street, Ste. 1600
13
              (C) CITY: Minneapolis
14
15
              (D) STATE: MN
16
              (E) COUNTRY: USA
              (F) ZIP: 55402
17
18
            (V) COMPUTER READABLE FORM:
19
20
              (A) MEDIUM TYPE: Diskette
              (B) COMPUTER: IBM Compatible
21
              (C) OPERATING SYSTEM: DOS
22
23
              (D) SOFTWARE: FastSEQ Version 2.0b
24
25
            (vi) CURRENT APPLICATION DATA:
26
              (A) APPLICATION NUMBER: 09/096,749
27
              (B) FILING DATE: June 12, 1998
28
29
            (vii) PRIOR APPLICATION DATA:
30
              (A) APPLICATION NUMBER:
              (B) FILING DATE:
31
32
33
            (viii) ATTORNEY/AGENT INFORMATION:
34
              (A) NAME: Ann S. Viksnins
              (B) REGISTRATION NUMBER: 37,748
35
36
              (C) REFERENCE/DOCKET NUMBER: 109.034US1
37
            (ix) TELECOMMUNICATION INFORMATION:
38
39
              (A) TELEPHONE: (612) 373-6900
40
              (B) TELEFAX: (612) 339-3061
41
```

ERRORED SEQUENCES FOLLOW:

42

RAW SEQUENCE LISTING DATE: 09/09/98 PAGE: 2 PATENT APPLICATION US/09/096,749 TIME: 15:58:55 INPUT SET: S28504.raw (2) INFORMATION FOR SEQ ID NO:13: 273 274 (i) SEQUENCE CHARACTERISTICS: 275 276 (A) LENGTH: 59 base pairs (B) TYPE: nucleic acid 277 (C) STRANDEDNESS: single 278 279 (D) TOPOLOGY: linear 280 281 (ii) MOLECULE TYPE: cDNA 282 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO 283 format eva-see vin I en Eva Summary Steet 284 (V) FRAGMENT TYPE: 285 (vi) ORIGINAL SOURCE: 286 287 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: 288 CGGGATCCCA TATGCAGGTT TCTGATGTTC CGCGTGACCT GGAAGTTGTT 289 GCTGCGACC 290 59 🔍 291 292 (2) INFORMATION FOR SEQ ID NO:14: 293 294 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 55 base pairs 295 296 (B) TYPE: nucleic acid 297 (C) STRANDEDNESS: single 298 (D) TOPOLOGY: linear 299 Same 300 (ii) MOLECULE TYPE: cDNA 301 (iii) HYPOTHETICAL: NO 302 (iv) ANTI-SENSE: NO 303 (V) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: 305 306 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: 307 TAACTGCAGG AGCATCCCAG CTGATCAGCA GGCTAGTCGG GGTCGCAGCA 308 ACAAC 55 309 310 311 (2) INFORMATION FOR SEQ ID NO:15: 312 (i) SEQUENCE CHARACTERISTICS: 313 (A) LENGTH: 51 base pairs 314 315 (B) TYPE: nucleic acid (C) STRANDEDNESS: single 316 317 (D) TOPOLOGY: linear 318 (ii) MOLECULE TYPE: cDNA 319 320 (iii) HYPOTHETICAL: NO 321 (iv) ANTI-SENSE: NO 322 (V) FRAGMENT TYPE:

323

(vi) ORIGINAL SOURCE:

RAW SEQUENCE LISTING PATENT APPLICATION US/09/096,749

DATE: 09/09/98 TIME: 15:58:56

INPUT SET: S28504.raw

		INPUT SET: S28504.raw
	324	
	325	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
	326	N. R. and
	327	CTCCTGCAGT TACCGTGCGT TATTACCGTA TCACGTACGG TGAAACCGGT G
	328	51
	329	
	402	(2) INFORMATION FOR SEQ ID NO:20:
	403	
	404	(i) SEQUENCE CHARACTERISTICS:
>	405	(A) LENGTH: 55 base pairs
	406	(B) TYPE: nucleic acid
	407	(C) STRANDEDNESS: single
	408	(D) TOPOLOGY: linear
	409	
	410	(ii) MOLECULE TYPE: cDNA
	411	(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (iv) FRACMENT TYPE:
	412	(iv) ANTI-SENSE: NO
	413	(V) FRAGMENT TIPE:
	414	(vi) ORIGINAL SOURCE:
	415	
	416	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
	417	
	418	CGGGATCCGA GCTCGCTGGG CTGTCACCAC GGCCAGTAAC AGCGTATACA
>	419	GTGAT 55
	420	\cdot
	F00	(A) TYPODWARTON FOR GEO TO NO.07.
	529 530	(2) INFORMATION FOR SEQ ID NO:27:
		(i) SECTIONCE CUADACTEDISTICS.
>	531	(i) SEQUENCE CHARACTERISTICS:
>	531 532	(A) LENGTH: 51 base pairs
>	531 532 533	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid
>	531 532 533 534	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single
>	531 532 533 534 535	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single
>	531 532 533 534 535 536	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single
>	531 532 533 534 535 536 537	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
>	531 532 533 534 535 536 537 538	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO
>	531 532 533 534 535 536 537	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
>	531 532 533 534 535 536 537 538 539	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO
>	531 532 533 534 535 536 537 538 539 540	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
>	531 532 533 534 535 536 537 538 539 540 541	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
>	531 532 533 534 535 536 537 538 539 540 541	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE:
>	531 532 533 534 535 536 537 538 539 540 541 542 543	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE:
>	531 532 533 534 535 536 537 538 539 540 541 542 543	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
>	531 532 533 534 535 536 537 538 539 540 541 542 543 544	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GATCAGCTGG GATGCTCCTN NKNNKNNKNN KNNKTATTAC CGTATCACGT A
>	531 532 533 534 535 536 537 538 539 541 542 543 544 545 546	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GATCAGCTGG GATGCTCCTN NKNNKNNKNN KNNKTATTAC CGTATCACGT A 51
>	531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GATCAGCTGG GATGCTCCTN NKNNKNNKNN KNNKTATTAC CGTATCACGT A
>	531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GATCAGCTGG GATGCTCCTN NKNNKNNKNN KNNKTATTAC CGTATCACGT A 51 (2) INFORMATION FOR SEQ ID NO:28:
>	531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GATCAGCTGG GATGCTCCTN NKNNKNNKNN KNNKTATTAC CGTATCACGT A 51
>	531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547	(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GATCAGCTGG GATGCTCCTN NKNNKNNKNN KNNKTATTAC CGTATCACGT A 51 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS:

RAW SEQUENCE LISTING PATENT APPLICATION US/09/096,749

DATE: 09/09/98 TIME: 15:58:57

```
INPUT SET: S28504.raw
554
               (D) TOPOLOGY: linear
555
556
             (ii) MOLECULE TYPE: cDNA
                                                                    some
557
             (iii) HYPOTHETICAL: NO
             (iv) ANTI-SENSE: NO
558
559
             (v) FRAGMENT TYPE:
560
             (vi) ORIGINAL SOURCE:
561
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
562
563
564
       TGTATACGCT GTTACTGGCN NKNNKNNKNN KNNKNNKNNK TCCAAGCCAA
565
     TCTCGAT
                     57
566
567
                (2) INFORMATION FOR SEQ ID NO:29:
568
             (i) SEQUENCE CHARACTERISTICS:
569
               (A) LENGTH: 47 base pairs
570
571
               (B) TYPE: nucleic acid
               (C) STRANDEDNESS: single
572
               (D) TOPOLOGY: linear
573
574
575
             (ii) MOLECULE TYPE: cDNA
576
             (iii) HYPOTHETICAL: NO
                                                                     some
577
             (iv) ANTI-SENSE: NO
             (V) FRAGMENT TYPE:
578
579
             (vi) ORIGINAL SOURCE:
580
581
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
582
583
      CTGTATACGC TGTTACTGGC NNKNNKNNKN NKCCAGCGAG CTCCAAG
584
     47
585
586
                (2) INFORMATION FOR SEQ ID NO:30:
587
588
             (i) SEQUENCE CHARACTERISTICS:
               (A) LENGTH: 51 base pairs
589
590
               (B) TYPE: nucleic acid
591
               (C) STRANDEDNESS: single
                                                              same
592
               (D) TOPOLOGY: linear
593
594
             (ii) MOLECULE TYPE: cDNA
595
             (iii) HYPOTHETICAL: NO
596
             (iv) ANTI-SENSE: NO
             (V) FRAGMENT TYPE:
597
598
             (vi) ORIGINAL SOURCE:
599
600
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
601
       CATCACTGTA TACGCTGTTA CTNNKNNKNN KNNKNNKTCC AAGCCAATCT C
602
603
       51
604
```

RAW SEQUENCE LISTING PATENT APPLICATION US/09/096,749

DATE: 09/09/98 TIME: 15:58:57

INPUT SET: S28504.raw

2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 > 2120 Thr Gly Gly Asn Ser Pro Val Oxx Gly 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	S: SEQ ID NO:110: U Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2100 2101 (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 94 amino acids 2103 (B) TYPE: amino acid 2104 (C) STRANDEDNESS: single 2105 (D) TOPOLOGY: linear 2106 2107 (ii) MOLECULE TYPE: peptide 2108 (iii) HYPOTHETICAL: NO 2109 (iv) ANTI-SENSE: NO 2110 (v) FRAGMENT TYPE: internal 2111 (vi) ORIGINAL SOURCE: 2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20> 2120 Thr Gly Gly Asn Ser Pro Val 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80	S: SEQ ID NO:110: U Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
(i) SEQUENCE CHARACTERISTICS	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
> 2102 (A) LENGTH: 94 amino acids 2103 (B) TYPE: amino acid 2104 (C) STRANDEDNESS: single 2105 (D) TOPOLOGY: linear 2106 2107 (ii) MOLECULE TYPE: peptide 2108 (iii) HYPOTHETICAL: NO 2109 (iv) ANTI-SENSE: NO 2110 (v) FRAGMENT TYPE: internal 2111 (vi) ORIGINAL SOURCE: 2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 5 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val Oxx Glu 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
(B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (D) TOPOLOGY: li	SEQ ID No:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
C	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2105 2106 2107 (ii) MOLECULE TYPE: peptide 2108 (iii) HYPOTHETICAL: NO 2109 (iv) ANTI-SENSE: NO 2110 (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: 2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20> 2120 Thr Gly Gly Asn Ser Pro Val (Oxx Gly 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2106 2107 (ii) MOLECULE TYPE: peptide 2108 (iii) HYPOTHETICAL: NO 2109 (iv) ANTI-SENSE: NO 2110 (v) FRAGMENT TYPE: internal 2111 (vi) ORIGINAL SOURCE: 2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
(ii) MOLECULE TYPE: peptide	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2108 (iii) HYPOTHETICAL: NO 2109 (iv) ANTI-SENSE: NO 2110 (v) FRAGMENT TYPE: internal 2111 (vi) ORIGINAL SOURCE: 2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2109 (iv) ANTI-SENSE: NO 2110 (v) FRAGMENT TYPE: internal 2111 (vi) ORIGINAL SOURCE: 2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2110 (v) FRAGMENT TYPE: internal 2111 (vi) ORIGINAL SOURCE: 2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2111 (vi) ORIGINAL SOURCE: 2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	SEQ ID NO:110: u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2112 2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val Oxx Glu 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2113 (xi) SEQUENCE DESCRIPTION: S 2114 2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly 2123 60 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2114 2115 2116	u Val Val Ala Ala Thr Pro Thr Ser Leu Leu 10 15 r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2115 2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 5 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val Oxx Glu 2121 40 45 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	10 15 If Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 U Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2116 Val Ser Asp Val Pro Arg Asp Leu Glu 2117 1 5 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val Oxx Glu 2121 40 45 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	10 15 If Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 U Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2117 1 5 2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25> 2120 Thr Gly Gly Asn Ser Pro Val Oxx Gly 2121 40 45 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	10 15 If Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 U Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 1 Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2118 Ile Ser Trp Asp Ala Pro Ala Val Thr 2119 20 25 > 2120 Thr Gly Gly Asn Ser Pro Val Oxx Gly 2121 40 45 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	r Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu 30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 l Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2119 20 2120 Thr Gly Gly Asn Ser Pro Val Oxx Gly 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser 85 2126 80 85	30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 l Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2119 20 Thr Gly Gly Asn Ser Pro Val Oxx Gly 2121 40 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser 85 2126 80 85	30 35 u Phe Thr Val Pro Gly Ser Lys Ser Thr Ala 50 55 l Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2121 40 45 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	50 55 l Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2121 40 45 2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85	50 55 l Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 70 75
2122 Thr Ile Ser Gly Leu Lys Pro Gly Val 2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85 2126	70 75
2123 60 65 2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85 2126	70 75
2124 Gly Arg Gly Asp Ser Pro Ala Ser Ser 2125 80 85 2126	
2125 80 85	
	90 (/) /
	involved and all see 1.822(b) of
	more on 100 100 1200 1.022(0) 0
2127 (2) INFORMATION FOR SEQ 1	ID NO:111:
2128	segure full
2129 (i) SEQUENCE CHARACTERISTICS	s:
> 2130 (A) LENGTH: 248 base pairs	s
2131 (B) TYPE: nucleic acid	100 Den
2132 (C) STRANDEDNESS: single	(1200)
2133 (D) TOPOLOGY: linear	0 4
2134	1 m Same
2135 (ii) MOLECULE TYPE: cDNA	101-0000
•	Ŋ
` ,	Jumes
· · ·	· · · · · · · · · · · · · · · · · · ·
`	10 4
	fler
, , ,	SEC ID NO. 111.
21/2	SEQ ID NO: 111:
2142 2143 CTCCTCATCA CCTCCCATCC TCCTCCACTT A	SEQ ID NO: 111:
2143 CTGCTGATCA GCTGGGATGC TCCTGCAGTT A	SEQ ID NO: 111: ACCGTGCGTT ATTACCGTAT 60 where are
2143 CŢGCTGATCA GCTGGGATGC TCCTGÇAGTT A 2144 CACGTĄCGGT	SEQ ID NO: 111: ACCGTGCGTT ATTACCGTAT 60 where are Cumulate
2143 CȚGCTGATCA GCTGGGATGC TCCTGCAGTT A 2144 CACGTACGGT 2145	SEQ ID NO: 111: ACCGTGCGTT ATTACCGTAT 60 where are Cumulate
2143 CȚGCTGATCA GCTGGGATGC TCCTGÇAGTT A 2144 CACGTACGGT 2145 2146 GAAACCGGTG GTAACTCCCC GGTTCAGGAA 1	SEQ ID NO: 111: ACCGTGCGTT ATTACCGTAT TTCACTGTAC CTGGTTCCAA Tan Loo
2143 CȚGCTGATCA GCTGGGATGE TCCTGÇAGTT A 2144 CACGTACGGT 2145 2146 GAAACCGGTG GTAACTCCCC GGTTCAGGAA 1 2147 GTCTACTGCT	SEQ ID NO: 111: ACCGTGCGTT ATTACCGTAT 60 where are Cumulate TTCACTGTAC CTGGTTCCAA Tou Look
2143 CȚGCTGATCA GCTGGGATGE TCCTGÇAGTT A 2144 CACGTACGGT 2145 2146 GAAACCGGTG GTAACTCCCC GGTTCAGGAA 1 2147 GTCTACTGCT 2148	TTCACTGTAC CTGGTTCCAA TOSI SINGLAR AND SINGLAR TOSI SINGLAR AND SINGLAR AND SINGLAR TOSI SINGLAR AND SINGLAR TOSI SINGLAR AND SINGLAR TOSI SINGLAR
2143 CȚGCTGATCA GCTGGGATGC TCCTGÇAGTT A 2144 CACGTACGGT 2145 2146 GAAACCGGTG GTAACTCCCC GGTTCAGGAA 1 2147 GTCTACTGCT	at lad of
2143 CȚGCTGATCA GCTGGGATGE TCCTGÇAGTT A 2144 CACGTACGGT 2145 2146 GAAACCGGTG GTAACTCCCC GGTTCAGGAA 1 2147 GTCTACTGCT 2148	at lad of
2143 CȚGCTGATCA GCTGGGATGE TCCTGÇAGTT A 2144 CACGTACGGT 2145 2146 GAAACCGGTG GTAACTCCCC GGTTCAGGAA T 2147 GTCTACTGCT 2148	at lad of
2136 (iii) HYPOTHETICAL: NO 2137 (iv) ANTI-SENSE: NO 2138 (v) FRAGMENT TYPE: 2139 (vi) ORIGINAL SOURCE: 2140 2141 (xi) SEQUENCE DESCRIPTION: S	ID NO: 111: S: Segvise Re Sele vien 7 or Eng furman

RAW SEQUENCE LISTING PATENT APPLICATION US/09/096,749

DATE: 09/09/98 TIME: 15:58:58

>	2155	GAGGATCC						248
	2154							
	2153	CTAGTAACTC						
	2152	CGTGGTGACA	GCCCAGCGAG	CTCCAAGCCA	ATCTCGATTA	ACTACCGTAC		
	2151							
	2150	TGTTACTGGC						
						IN	PUT SET: S28504.rd	IW


No.

SEQUENCE VERIFICATION REPORT PATENT APPLICATION US/09/096,749

DATE: 09/09/98 TIME: 15:59:02

INPUT SET: S28504.raw

Line	Error	Original Text
276 290	Entered (59) and Calc. Seq. Length (9) differ # of Sequences for line conflicts w/ running total	(A) LENGTH: 59 base pairs GCTGCGACC 59
295 309	Entered (55) and Calc. Seq. Length (5) differ # of Sequences for line conflicts w/ running total	(A) LENGTH: 55 base pairs ACAAC 55
314	Entered (51) and Calc. Seq. Length (0) differ	(A) LENGTH: 51 base pairs
405 419	Entered (55) and Calc. Seq. Length (5) differ # of Sequences for line conflicts w/ running total	(A) LENGTH: 55 base pairs GTGAT 55
532	Entered (51) and Calc. Seq. Length (0) differ	(A) LENGTH: 51 base pairs
551 565	Entered (57) and Calc. Seq. Length (7) differ # of Sequences for line conflicts w/ running total	(A) LENGTH: 57 base pairs TCTCGAT 57
570 589	Entered (47) and Calc. Seq. Length (0) differ Entered (51) and Calc. Seq. Length (0) differ	(A) LENGTH: 47 base pairs (A) LENGTH: 51 base pairs
2102	Entered (94) and Calc. Seq. Length (93) differ	(A) LENGTH: 91 base pairs (A) LENGTH: 94 amino acids
2120 2130	Wrong Amino Acid Designator Entered (248) and Calc. Seq. Length (8) differ	Thr Gly Gly Asn Ser Pro Val Oxx Glu Phe Thr Val Pro Gly (A) LENGTH: 248 base pairs
2155	# of Sequences for line conflicts w/ running total	GAGGATCC



Notice of Availability of Checker Program

Applicant Aid for Biotechnology Computer Readable Form (CRF)
Sequence Listing Submissions

The Patent and Trademark Office (PTO) has developed a computer program, called Checker, that will aid applicants in identifying and correcting errors prior to making submissions for compliance with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (Sequence Rules: 37CRF 1.821 through 1.825). Final rules were published in the Federal Register (55 FR18230) on May 1, 1990, and in the PTO Official Gazette (1114 Off.Gaz.PatOffice 29) on May 15, 1990.

Checker is a DOS-based software program that is intended to assist users in determining whether errors may be present in the sequence listings, and is not intended to guarantee that the submission is error-free.

The most current version of the software is available via computer downloading, details are below. Copies on diskette are also available. Updated software versions will not be automatically mailed out; any updates will be announced in the PTO Official Gazette.

The software can be accessed/requested from the following locations:

- Dial-up access through the Internet. Location is ftp://ftp.uspto.gov
 The software is in current directory: pub/checker/
 Download all the files. Cost: Free-of-charge
- 3) For diskette copies, mail to: U.S.P.T.O., OEIP, CRYSTAL PARK 3, SUITE 441 WASHINGTON DC 20231

COST FOR DISKETTE IS <u>\$ 25.00</u> METHOD OF PAYMENT:

Check payable to Commissioner of Patents and Trademarks VISA/ Mastercard/ Charge- Charges can be faxed to 703-306-2737 PTO Deposit Account

For Further Information, Contact: Arti Shah at 703-308-4212